JAK1 and synovial sarcoma: In this sense, it is worth knowing that no significant improvement in SS symptoms was observed in a phase II study examining the effects of an inhibitor of Jak1, an indispensable signaling molecule whose action is mediated via IFN-γ receptors [23].